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Introduction: Disease-modifying antirheumatic drugs (DMARDs) have become the treatment standard for patients
with rheumatoid arthritis (RA). Although several general-population studies document that a large population of
patients diagnosed with RA do not use DMARDs, little is known about this group. We explored the characteristics,
experiences, and knowledge of a low-income, elderly RA population not currently using DMARDs, or receiving care
from a rheumatologist.
Methods: We administered structured telephone interviews to participants enrolled in a large pharmacy benefits
program for the elderly who had two diagnoses of RA ≥7 days apart and no DMARD prescriptions or
rheumatologist visits in the prior year. The interview contained questions concerning each participant’s
sociodemographic information, disease activity, DMARD experiences, and the Modified Health Assessment
Questionnaire (MHAQ). We described responses and compared prior users with never users.
Results: A total of 86 people completed the interview. The mean age was 80 years and 89% were female. On
average, disease duration was 20 years. Mean MHAQ score was 0.55 (SD = 0.55). Of 86 participants, 19 had
previously used DMARDs, 10 of whom discontinued them because of side effects or safety concerns. Among 67
never-users, 35 (52.2%) reported that their physicians had never offered them DMARDs, 13 (19.4%) described fear of
side effects, and 49 (73.1%) knew nothing about them. Prior-users reported experiencing more-severe RA symptoms
than never-users.
Conclusions: We found that side effects or safety concerns were the primary cause for DMARD cessation among
prior-users. Among never-users, most reported never discussing or being offered DMARDs, suggesting that an
educational gap may deter patients with RA from using them.Introduction
Rheumatoid arthritis (RA) is a chronic systemic auto-
immune inflammatory disorder that increases the risk of
disability and early mortality [1]. The disease manifests
itself primarily in joint damage through synovial inflam-
mation but has been shown to negatively impact respi-
ratory, cardiac, neurologic, and hematologic systems
as well [2]. It is estimated to affect between 0.5% and
1.0% of the adult population worldwide, with a higher* Correspondence: dsolomon@partners.org
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reproduction in any medium, provided the orprevalence among women and the elderly [1]. Some
studies demonstrate reduced life span in RA [3-6].
Disease-modifying antirheumatic drugs (DMARDs) have
been recommended as the standard of care because of their
consistent reduction of pain and disability in patients that
have lived RA for several decades [7]. Studies demonstrate
that delays in the implementation of DMARD treatment
have been associated with increased physical disability,
radiologic damage, and other long-term health outcomes
[8,9]. As a result, the American College of Rheumatology
(ACR) and European League Against Rheumatism both
recommend early and aggressive DMARD treatment to es-
sentially all patients with RA [10,11].
Despite these recommendations, DMARD treatment
rates among RA patients are suboptimal. InvestigatorsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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iveness Data and Information Set data demonstrated that
only 63% of RA patients used DMARDs, and use was 30%
less likely among patients older than 85 years [12]. Several
other insurance claims-based studies have confirmed that
increasing age may act as a deterrent for using DMARDs
[13-15]. Low-socioeconomic status and lack of rheumatic
disease specialty care have also been identified as predictors
of suboptimal DMARD use in populations, after adjusting
for health care and drug-insurance benefits [15,16].
Although rates of DMARD use have been found to be
low in multiple studies, we are not aware of any prior
interview studies examining why certain populations do
not use DMARDs. Much of the literature that currently
exists comes from administrative claims data, which in-
trinsically lack insight into why individuals stopped or
never started a DMARD regimen. This study aims to fill
the current gaps in our understanding of the experiences,
perceptions, and knowledge among a population of RA
patients that has never used or stopped using DMARDs.Methods
Participants
We performed structured telephone interviews with 86 pa-
tients with RA to better to understand the determinants
and barriers to DMARD use in a low-income, elderly, and
primarily female sample population. We obtained eligible
subjects’ contact information from the Pharmaceutical As-
sistance Contract for the Elderly (PACE) in Pennsylvania, a
program that provides assistance for individuals who are
older than 65 years and have an annual income of less
than $17,000. The PACE program supplied us with the
contact information of individuals that had received a
minimum of two RA diagnoses and had no prescription
for DMARDs in the prior year.
The inclusion criteria for participation were eligibility
for the PACE program, two physician visits coded with of
a diagnosis of RA at least 7 days apart, a subject’s confirm-
ation of his or her RA diagnosis, no prescriptions for
DMARDs in the prior 12 months, and no rheumatologist
visits. We excluded patients with recent rheumatology
visits because one of our goals was to understand better
why patients who see primary care providers for their RA
do not use DMARDs.
We received ethical approval from the Partners Human
Research Committee to carry out each aspect of this pro-
ject, and all participants gave informed consent before
their interviews.Interview and recruitment
We chose a two-phase system for recruitment and used
US mail as our first point of contact. Subjects who did
not opt out by mail were contacted by telephone. A $5gift card was provided to individuals that completed the
interview.
The interview consisted of items regarding RA, partici-
pants’ prior DMARD use, knowledge, and experience with
DMARDs, the Modified Health Assessment Questionnaire
(MHAQ), and subject’s sociodemographic information.
We asked participants to self-report the frequency and se-
verity of their joint stiffness, swelling by joint location
(wrist, finger, elbow, knee), whether they had a blood test
for RA, and if so, if it was positive or negative, and if they
had nodules or bumps around their skin. To assess
DMARD use, we read subjects a list of 12 common medi-
cations (generic and manufactured names) and asked if
they had used one or multiple DMARDs in the past.
Knowledge was determined by listing the names of
DMARDs and asking participants open-ended questions
regarding how much they knew about the routes of ad-
ministration, side effects, benefits, costs, and drug interac-
tions of each one. We asked never-users why they never
started a DMARD regimen and prior-users why they
ceased DMARD use. We also inquired whether prior
DMARD users would consider using a different drug for
their RA.Statistical analysis
Analyses were descriptive and did not test specific hypoth-
eses. Qualitative responses to the open-ended structured
interview questions were grouped into categories to facili-
tate analysis; quantitative responses were described by
using means with standard deviations (SD) and counts.
The group of respondents reporting prior use of DMARDs
was compared with the never-users by using χ2 or Student
t tests. We examined the specific DMARDs used by prior-
users and reasons for discontinuation. Finally, the never-
users’ responses to questions regarding attitudes and
knowledge about DMARDs were examined. All analyses
were conducted by using SAS 9.2 (Cary, NC, USA).Results
We sent 1,586 invitations to all eligible PACE participants
via US mail. Of these, 162 (10.2%) participants chose to
opt out, and 312 (19.7%) could not be delivered. We
attempted telephone contact with the remaining 1,112
(70.1%), of whom 321 (20.2%) could not be reached be-
cause of a disconnected telephone line; 178 (11.2%) did
not pick up the telephone; 156 (9.8%) were reported de-
ceased; 14 (0.9%) could not speak English; 116 (7.3%) de-
nied RA; 49 (3.1%) had seen a rheumatologist with the
past year; and 2 (0.1%) reported using DMARDs.
Of the remaining 274 eligible subjects, 188 of them re-
fused to participate. Detailed information about this co-
hort assembly can be found in Figure 1. Our final study
cohort consisted of 86 participants.
Figure 1 Assembly of the study cohort. RA, rheumatoid arthritis; DMARD, disease-modifying antirheumatic drug.
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teristics of our sample can be found in Table 1. The mean
age of participants was 80 years; they were primarily
women (89.5%) that held a high-school diploma (51.2%),
and had an annual income of less than $25,000 (95.3%).
On average, participants had been living with RA for 20
years; 73.3% of participants felt joint stiffness in the morn-
ing, and 61.6% self reported feeling two or more swollen
joints. Only 45.3% reported having ever seen a rheuma-
tologist. The mean MHAQ score was 0.6 (SD, 0.6).
Nineteen participants reported prior DMARD use. We
report the specific drugs they discontinued and reasons i
for stopping in Table 2. Five participants had previously
used more than one DMARD. The majority of partici-
pants (n = 10, or 52.6%) had used methotrexate, of whom
half stopped because of side effects. Approximately one-
third had (n = 6) used hydroxychloroquine, 33.3% (n = 2)
discontinued the drug per physician’s request, and 33.3%
(two) because of inefficacy. Twenty-one percent of prior
DMARD users (n = 4) had used gold.
Side effects and concerns about side effects accounted
for 52.6% of cessations, and inefficacy comprised 42.1%.
Physicians’ requests to terminate DMARD therapy re-
sulted in 21.1% of discontinuations, cost accounted for
10.5%, and inconvenience only made up 5.3%. However,
when asked about knowledge relating to the side effects,
costs, benefits, method of administration, or other as-
pects of specific DMARDs, few of the nonusers demon-
strated any accurate knowledge.
Prior DMARD users reported more-severe RA symp-
toms and longer disease duration than did never-users.
They had a significantly higher range of MHAQ scores
than did never-users (P <0.05). Approximately two thirdsof never-users reported joint stiffness in the morning,
whereas nearly 90% of prior-users did (P = 0.07). Although
42.1% of prior-users reported four or more swollen joints,
only 20.9% of never-users reported experiencing the same
severity (P = 0.06). Prior-users reported living with RA for
an average of 25 years, and never-users reported an aver-
age of 18 years (P = 0.13). Participants that had previously
used DMARDs also reported more specialized services;
84.2% indicated that they had serologic blood work done,
whereas only 50.7% of never-users did (P = 0.06), and
78.9% stated that they had seen a rheumatologist, whereas
35.8% of never-users did (P < 0.01).
We were also interested in the knowledge and attitudes
of DMARDs among never-users (Table 3). When asked
why they hadn’t started a DMARD regimen, 53.8% of
never-users stated they had never been offered DMARD
treatment. As well, 26.2% said they were unfamiliar with
DMARDs. In response to reasons that they would con-
sider using a DMARD, 18.5% of never-users said they
would use them to relieve pain or swelling, and 12.3% said
they would use them in accordance with a physician’s rec-
ommendation. One participant indicated that she would
use them to stop joint damage. Only 13.8% had spoken
with a physician about using DMARDs, and one individ-
ual reported researching DMARDs on her own. However,
the vast majority of never-users stated they knew nothing
about DMARDs.
Discussion
We studied a cohort of older RA patients who had not
filled prescriptions or received infusions for DMARDs in
the prior year. Our findings represent data from a sam-
ple of primarily elderly, low-income women who receive
Table 1 Characteristics of study population
Total Prior-users Never-users P value
N = 86 (100%) n = 19 (19%) n = 67 (81%)
Demographics
Age (Mean, SD) 80 (±10.3) 79 (±5.2) 80 (±11.3) 0.77
Female 77 (89.5%) 15 (78.9%) 62 (92.5%) (Mean, SD) 0.09
Race 0.64
White, non-Hispanic 83 (96.5%) 16 (94.7%) 64 (95.5%)
Black, non-Hispanic 3 (3.5%) 1 (5.3%) 2 (3.0%)
Education 0.77
Less than 8th grade 10 (11.6%) 3 (15.8%) 7 (10.4%)
Some high school 15 (17.4%) 4 (21.1%) 11 (16.4%)
High school graduate 44 (51.2%) 8 (42.1%) 36 (53.7%)
Some college or greater 15 (17.4%) 4 (21.1%) 11 (16.4%)
Unknown 2 (2.3%) 0 (0.0%) 2 (3.0%)
Income 0.59
Below $25,000 82 (95.3%) 19 (100%) 63 (94.0%)
Above $25,000 1 (1.2%) 0 (0.0%) 1 (1.5%)
Unknown 3 (3.5%) 0 (0.0%) 3 (4.5%)
RA characteristics
Morning stiffness 63 (73.3%) 17 (89.5%) 46 (68.7%) 0.07
Nodules around elbow/ankle 13 (15.1%) 3 (15.8%) 10 (14.9%) 0.93
Self-reported swollen joints 0.06
Zero 28 (32.6%) 4 (21.1%) 24 (34.8%)
One 5 (5.8%) 1 (5.3%) 4 (6.0%)
Two 21 (24.4%) 3 (15.8%) 18 (26.9%)
Three 10 (11.6%) 3 (15.8%) 7 (10.4%)
Four or more 22 (25.6%) 8 (42.1%) 15 (20.9%)
Self-reported serologic status 50 (58.1%) 16 (84.2%) 34 (50.7%) 0.06
Positive 21 (24.4%) 10 (52.6%) 11 (16.4%)
Negative 2 (2.3%) 1 (5.3%) 1 (1.5%)
Do not know 25 (29.1%) 4 (21.1%) 21 (31.3%)
Years with RA (mean, SD) 20 ± 15.9 25 ± 17.6 18 ±15.2 0.13
MHAQ (mean, SD) 0.5 ± 0.5 0.8 ± 0.6 0.5 ± 0.5 0.02
0 18 (20.9%) 1 (5.3%) 19 (28.4%) 0.01
>0-1 53 (61.6%) 12 (63.2%) 41 (61.2%)
>1-2 11 (12.8%) 5 (26.3%) 6 (9.0%)
>2-3 2 (2.3%) 1 (5.3%) 1 (1.5%)
Prior visit with rheum >1 year ago 39 (45.3%) 15 (78.9%) 27 (35.8%) 0.01
MHAQ, Modified Health Assessment Questionnaire; RA, rheumatoid arthritis; SD, standard deviation.
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rheumatologists. Although several general-population
studies document that a large population of patients di-
agnosed with RA do not use DMARDs, they do not
examine the rationale behind nonuse.
To better understand the reasons for DMARD nonuse,
we conducted structured interviews by speaking directlywith a group of non-users’ about their attitudes, know-
ledge, and experience regarding the medications. We
spoke with 86 participants, and found that among 19
prior-users, side effects or safety concerns were the primary
causes for DMARD cessation. Prior-users also described
more-severe RA symptoms than did never-users. Among
67 never-users, most reported never discussing or being
Table 2 Reasons for DMARD discontinuation among 19 prior-users
N (%) Side effects experienced Physician’s request Cost Concernsa Inconvenient Ineffective Otherb
Methotrexate 10 (52.6) 5 1 2 1 1 2 0
Hydroxychloroquine 6 (31.6) 1 2 0 1 0 2 1
Abatacept 1 (5.3) 0 0 0 0 0 1 0
Etanercept 2 (10.5) 0 0 0 0 0 1 1
Infliximab 1 (5.3) 0 0 0 0 0 1 0
Gold 4 (21.1) 1 1 0 1 0 1 1
Totalc 24 7 4 2 3 1 8 3
aConcerns about possible side effects or drug reactions that were not already experienced.
bOther health problems.
cParticipants were allowed to report more than one DMARD discontinuation.
Table 3 Attitudes and knowledge of DMARDs among 65
never-users
Never-users
What are some reasons you never started DMARDs?
Never heard of DMARDs 17 (26.2%)
Never been offered DMARDs 35 (53.8%)
Do not need DMARDs 10 (15.4%)
Afraid of DMARRD side effects 13 (20.0%)
Taking too many other medications 8 (12.3%)
Do not see physicians often 1 (1.5%)
Other medical problems take precedence 2 (3.1%)
Inconvenience 1 (1.5%)
What are some reasons you would use a DMARD?
Stops joint damage 1 (1.5%)
Relieves pain or swelling 12 (18.5%)
Physician recommendation 8 (12.3%)
If rheumatoid arthritis worsens 1 (1.5%)
If the DMARD has no side effects 1 (1.5%)
Have you ever talked to a physician about any DMARDs?
Yes 9 (13.8%)
No 56 (86.2%)
Have you ever looked up information about DMARDs?
Yes 1 (1.5%)
No 64 (98.5%)
Do you know anything about DMARDs in general?
Side effects 11 (16.9%)
Benefits 1 (1.5%)
Method of administration 1 (1.5%)
Nothing 53 (81.5%)
Total missing 2
Of the 67 never–users, 65 answered these questions.
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deter patients with RA from starting a DMARD regimen.
Our findings must be interpreted with some limitations
in mind. First, we conducted structured interviews with a
fairly small cohort, which affects its generalizability. The
study interviews were 20 to 25 minutes in length, hinder-
ing recruitment, but allowing us to collect a larger amount
of detailed data from a smaller sample.
Second, our participants were a homogeneous group
of low-income, older non-users that (a) had drug insur-
ance, and (b) had not seen a rheumatologist recently;
these may limit the generalizability of their responses to
the factors RA population. However, low-income, elderly
individuals with RA are a group known from other
studies to be at high risk for not using DMARDs
[13-15], and their rationale for non-use is important.
The fact that they all have insurance reduced cost as a
factor for non-users.
Third, we cannot be absolutely certain that our partici-
pants had RA. We did our best to mitigate this issue by
limiting recruitment to patients with two physician-
reported RA diagnoses in their claims records and by
having participants confirm the physicians’ diagnosis.
Despite reporting no DMARD use, the study population
had relatively preserved functional status, as evidence by
a mean modified HAQ score of 0.5. It is likely that many
of our subjects had mild RA; it is even possible that
some would not fulfill criteria for RA, despite having a
diagnosis from a doctor and reporting joint symptoms.
According to several sets of guidelines [10,11], they
would most likely benefit from DMARDs. It is possible
that the study population, many of them anti-CCP nega-
tive and RF negative, may be less likely to be adherent
with DMARDs. Contraindications to DMARD use may
have also deterred them from using these agents.
Finally, is important to acknowledge that inaccurate
information may have been reported by prior- and
never–users, given that the mean disease duration of this
sample is 20 years, and subjects may not recall or
recognize using or learning about certain drugs.
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ported knowledge gap came from suboptimal patient edu-
cation. In a 2011 study, investigators found that primary
care physicians felt uncomfortable managing DMARDs,
and just over half knew when to prescribe them [17].
Given that many people living with RA in the United
States do not actively see a rheumatologist, and several
studies have demonstrated that patients’ personal beliefs
and education about the necessity of their medication have
been shown to affect greatly the courses of their medica-
tion [18,19], it is important that primary care providers
be knowledgeable about the disease and its treatment.
They should be able to discuss medication in a framework
understood by the patients to ensure that they are making
optimal decisions. The 26.2% of never-users stating they
had never heard of DMARDs and 53.8% stating they had
never been offered them would have likely benefited from
such a conversation with a provider.
An expansion of education among nonspecialists would
enable providers to feel more comfortable discussing
DMARDs and provide better information to patients so
they could make well-informed treatment-related deci-
sions. More never-users would likely start using DMARDs,
and non-users that would benefit from DMARD therapy
would have a higher chance of reengaging as well. Despite
reporting experiencing active symptoms of RA, only five
of the 19 patients from this sample had tried using more
than one DMARD, despite the ACR recommendation for
patients with RA to try switching or using combination
therapy [10].
Improving access to rheumatic disease specialists would
more directly improve the probability that patients ex-
periencing RA symptoms would use DMARDs. In 2007,
a study by Deal et al. [20] showed that the incidence of
rheumatologic and musculoskeletal diseases started to
exceed the supply of rheumatologists in 2005 and pre-
dicts it will continue to do so through 2025. As such,
the rheumatology community should start considering
solutions to this pressing issue. One proposition is
to expand the roles of mid-level practitioners such as
nurse practitioners and physician assistants in rheu-
matology practices to enhance practice efficiency and
increase the availability of less-complex services to pa-
tients [20]. We believe that mid-level practitioners’ abil-
ity to prescribe and monitor DMARD use will allow
quicker and more-efficient drug use, ideally producing
less need for long-term management by rheumatolo-
gists. Socioeconomic status, geographic location and ac-
cess to care, comorbidities, patients’ knowledge and
beliefs, physicians’ behaviors, and age have all de-
monstrated important roles in shaping patients’ health
behaviors, affecting health outcomes [21,22]. Without
acknowledging patients’ priorities and limitations, we
cannot provide adequate care; therefore, understandingthese issues is crucial for conducting effective medical
practice.
Conclusions
We interviewed a sizeable group of older, low-income,
female adults with RA. This population included prior
DMARD users and never-users, and they reported expe-
riencing symptoms that could likely be alleviated by
DMARDs. Lack of information and/or concerns about
side effects were major impediments to DMARD use. Al-
though this population is not representative of all RA pa-
tients, it is characterized by a number of attributes (for
example, low-income elderly with several comorbidities)
that are common in nonadherent RA patient populations.
Looking at their responses will help us better understand
populations that have been shown to be at high risk for
DMARD non-use.
Both non-users and never-users could benefit from in-
creased education at the patient and provider level. Edu-
cating primary care providers is important because it
would allow them to feel more knowledgeable discussing,
recommending, and prescribing DMARDs, which in turn
would make patients more comfortable using them. The
issue of non-use will likely grow as the gap between supply
and demand of providers worsens. Innovative programs to
extend the reach of rheumatic disease expertise must be a
top priority to improve the use of DMARDs for RA.
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